Atlas Trials

Novartis Pharmaceuticals

2,690 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Novartis Pharmaceuticals

RecordFirmDate
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (NCT01216072)Novartis Pharmaceuticals2010-08-01
Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension (NCT01193101)Novartis Pharmaceuticals2010-08-01
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis (NCT01090310)Novartis Pharmaceuticals2010-08-01
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (NCT01137682)Novartis Pharmaceuticals2010-07-19
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors (NCT01155713)Novartis Pharmaceuticals2010-07-01
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME) (NCT01135914)Novartis Pharmaceuticals2010-07-01
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) (NCT01179737)Novartis Pharmaceuticals2010-07-01
Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms (NCT01300416)Novartis Pharmaceuticals2010-07-01
Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis (NCT01148810)Novartis Pharmaceuticals2010-06-15
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib (NCT01223898)Novartis Pharmaceuticals2010-06-01
ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling (NCT01176032)Novartis Pharmaceuticals2010-06-01
Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment (NCT01613690)Novartis Pharmaceuticals2010-06-01
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (NCT01028222)Novartis Pharmaceuticals2010-06-01
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (NCT01131585)Novartis Pharmaceuticals2010-06-01
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients (NCT01129336)Novartis Pharmaceuticals2010-06-01
Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01154127)Novartis Pharmaceuticals2010-06-01
Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics (NCT00997477)Novartis Pharmaceuticals2010-06-01
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis (NCT01169844)Novartis Pharmaceuticals2010-06-01
Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) (NCT01155700)Novartis Pharmaceuticals2010-06-01
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age (NCT01150357)Novartis Pharmaceuticals2010-06-01
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) (NCT01034163)Novartis Pharmaceuticals2010-06-01
Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes (NCT01159249)Novartis Pharmaceuticals2010-06-01
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (NCT01083602)Novartis Pharmaceuticals2010-06-01
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) (NCT01156415)Novartis Pharmaceuticals2010-06-01
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma (NCT01147822)Novartis Pharmaceuticals2010-05-19
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer (NCT01064310)Novartis Pharmaceuticals2010-05-17
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis (NCT01132612)Novartis Pharmaceuticals2010-05-11
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (NCT01039376)Novartis Pharmaceuticals2010-05-06
Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study. (NCT01056822)Novartis Pharmaceuticals2010-05-01
Efficacy of QAX576 in Asthma (NCT01130064)Novartis Pharmaceuticals2010-05-01
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer (NCT01132664)Novartis Pharmaceuticals2010-05-01
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients (NCT01119937)Novartis Pharmaceuticals2010-05-01
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (NCT01110889)Novartis Pharmaceuticals2010-05-01
A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure (NCT01125514)Novartis Pharmaceuticals2010-05-01
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer (NCT01152801)Novartis Pharmaceuticals2010-05-01
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria (NCT01228344)Novartis Pharmaceuticals2010-05-01
Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia (NCT01146522)Novartis Pharmaceuticals2010-05-01
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia (NCT01163227)Novartis Pharmaceuticals2010-05-01
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD) (NCT01110902)Novartis Pharmaceuticals2010-05-01
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase (NCT01061177)Novartis Pharmaceuticals2010-05-01
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation (NCT01058434)Novartis Pharmaceuticals2010-05-01
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients (NCT01155453)Novartis Pharmaceuticals2010-04-01
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis (NCT01095250)Novartis Pharmaceuticals2010-04-01
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer (NCT01084330)Novartis Pharmaceuticals2010-04-01
To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol (NCT01272362)Novartis Pharmaceuticals2010-04-01
Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients (NCT01128335)Novartis Pharmaceuticals2010-04-01
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (NCT01120691)Novartis Pharmaceuticals2010-04-01
Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis (NCT01460836)Novartis Pharmaceuticals2010-04-01
To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee (NCT01160822)Novartis Pharmaceuticals2010-04-01
A Study to Assess the Long-term Safety of QVA149 (NCT01120717)Novartis Pharmaceuticals2010-04-01
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01119950)Novartis Pharmaceuticals2010-04-01
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease (NCT01047579)Novartis Pharmaceuticals2010-04-01
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis (NCT01109940)Novartis Pharmaceuticals2010-04-01
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (NCT01117987)Novartis Pharmaceuticals2010-04-01
Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever (NCT01088880)Novartis Pharmaceuticals2010-04-01
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. (NCT01035229)Novartis Pharmaceuticals2010-04-01
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years (NCT01082367)Novartis Pharmaceuticals2010-04-01
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis (NCT00572585)Novartis Pharmaceuticals2010-04-01
Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients (NCT01150097)Novartis Pharmaceuticals2010-03-31
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 (NCT01072175)Novartis Pharmaceuticals2010-03-26
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (NCT00940602)Novartis Pharmaceuticals2010-03-22
A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine (NCT01103050)Novartis Pharmaceuticals2010-03-22
Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma (NCT01103037)Novartis Pharmaceuticals2010-03-01
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function (NCT00997399)Novartis Pharmaceuticals2010-03-01
Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections (NCT01184872)Novartis Pharmaceuticals2010-03-01
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. (NCT01080131)Novartis Pharmaceuticals2010-03-01
Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections (NCT01019980)Novartis Pharmaceuticals2010-03-01
Phase II Study of TKI258 in Advanced Urothelial Carcinoma (NCT00790426)Novartis Pharmaceuticals2010-03-01
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) (NCT01089127)Novartis Pharmaceuticals2010-03-01
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function (NCT01278758)Novartis Pharmaceuticals2010-03-01
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis (NCT01071252)Novartis Pharmaceuticals2010-03-01
38 Week Extension Study to CAIN457C2303 (NCT01093846)Novartis Pharmaceuticals2010-03-01
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients (NCT01097096)Novartis Pharmaceuticals2010-03-01
Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol (NCT01156844)Novartis Pharmaceuticals2010-03-01
Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function (NCT01007968)Novartis Pharmaceuticals2010-03-01
Second Open Label Extension to Bridging Study CTBM100C2303 (NCT01069705)Novartis Pharmaceuticals2010-02-12
Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension (NCT01080768)Novartis Pharmaceuticals2010-02-01
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors (NCT01030055)Novartis Pharmaceuticals2010-02-01
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis (NCT01032915)Novartis Pharmaceuticals2010-02-01
Efficacy and Safety of Different Doses of Indacaterol (NCT01079130)Novartis Pharmaceuticals2010-02-01
Dose Escalation of HSP990 in Japan/Korea (NCT01064089)Novartis Pharmaceuticals2010-02-01
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies (NCT01290380)Novartis Pharmaceuticals2010-02-01
Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) (NCT01148511)Novartis Pharmaceuticals2010-02-01
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone (NCT00968968)Novartis Pharmaceuticals2010-01-20
An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 (NCT01240642)Novartis Pharmaceuticals2010-01-01
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis (NCT01059318)Novartis Pharmaceuticals2010-01-01
Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT01068613)Novartis Pharmaceuticals2010-01-01
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function (NCT01278849)Novartis Pharmaceuticals2010-01-01
Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients (NCT01025817)Novartis Pharmaceuticals2010-01-01
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (NCT01023308)Novartis Pharmaceuticals2009-12-21
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies (NCT01004224)Novartis Pharmaceuticals2009-12-11
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). (NCT00946647)Novartis Pharmaceuticals2009-12-02
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study (NCT01029652)Novartis Pharmaceuticals2009-12-01
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (NCT01043874)Novartis Pharmaceuticals2009-12-01
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients (NCT00965094)Novartis Pharmaceuticals2009-12-01
Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients (NCT01064791)Novartis Pharmaceuticals2009-12-01
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler (NCT01051817)Novartis Pharmaceuticals2009-12-01
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients (NCT00995930)Novartis Pharmaceuticals2009-12-01
To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC) (NCT01033019)Novartis Pharmaceuticals2009-12-01
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. (NCT01250951)Novartis Pharmaceuticals2009-12-01
← Previous Next →

Track Novartis Pharmaceuticals automatically

Every clearance here is in the API, with alerts when new ones post.